-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 25, Renfu Pharma announced that the clinical application for the Class 1 new drug RFUS-144 injection of its holding subsidiary Yichang Renfu was accepted by CDE
.
The drug is a selective opioid receptor agonist.
According to data from Minet.
com, in 2020, the sales of terminal opioid painkillers in Chinese public medical institutions exceeded 12.
6 billion yuan
.
RFUS-144 injection is intended to be clinically used for the treatment of pain and pruritus.
It is a selective opioid receptor agonist, and there is currently no similar product on the market in China
.
Up to now, the accumulated investment of Yichang Renfu project is about 11 million yuan
.
According to data from Minet.
com, in 2020, the sales of terminal opioid painkillers in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 12.
6 billion yuan, and in the first half of 2021, its sales were close to 6.
7 billion yuan, a year-on-year increase of 16.
26%
.
The sales of three varieties including dezocine, butorphanol and oxycodone ranked among the top three
.
Sales of terminal opioid analgesics in public medical institutions in China (unit: 10,000 yuan) Source: Minet
.
RFUS-144 injection is Renfu Medicine's first Class 1 new drug to apply for clinical application this year
.
In addition to Category 1 new drugs, Renfu Medicine has also made a series of progress in the field of improved new drugs this year, including the application for listing of isoflurane injection, oxycodone sustained-release tablets of paracetamol, dexmedetomidine hydrochloride nasal spray, dexamethasone Three new drugs, including Detomidine Transdermal Patch (II), were approved for clinical use
.
Data source: Minet database, CDE
.
The drug is a selective opioid receptor agonist.
According to data from Minet.
com, in 2020, the sales of terminal opioid painkillers in Chinese public medical institutions exceeded 12.
6 billion yuan
.
RFUS-144 injection is intended to be clinically used for the treatment of pain and pruritus.
It is a selective opioid receptor agonist, and there is currently no similar product on the market in China
.
Up to now, the accumulated investment of Yichang Renfu project is about 11 million yuan
.
According to data from Minet.
com, in 2020, the sales of terminal opioid painkillers in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 12.
6 billion yuan, and in the first half of 2021, its sales were close to 6.
7 billion yuan, a year-on-year increase of 16.
26%
.
The sales of three varieties including dezocine, butorphanol and oxycodone ranked among the top three
.
Sales of terminal opioid analgesics in public medical institutions in China (unit: 10,000 yuan) Source: Minet
.
RFUS-144 injection is Renfu Medicine's first Class 1 new drug to apply for clinical application this year
.
In addition to Category 1 new drugs, Renfu Medicine has also made a series of progress in the field of improved new drugs this year, including the application for listing of isoflurane injection, oxycodone sustained-release tablets of paracetamol, dexmedetomidine hydrochloride nasal spray, dexamethasone Three new drugs, including Detomidine Transdermal Patch (II), were approved for clinical use
.
Data source: Minet database, CDE
